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REVIEW
Abstract: Strontium ranelate is a new orally administered agent for the treatment of women 
with postmenopausal osteoporosis that reduces the risk of vertebral and hip fractures. Evidence 
for the safety and efﬁ  cacy of strontium ranelate comes from two large multinational trials, 
the SOTI (Spinal Osteoporosis Therapeutic Intervention) and TROPOS (Treatment Of 
Postmenopausal Osteoporosis) studies. The SOTI study evaluated vertebral fracture prevention 
in 1649 postmenopausal women with a mean age of 69 y. The subjects all had at least one 
previous vertebral fracture and a low spine bone mineral density (BMD) (equivalent to a 
Hologic spine T-score below –1.9). The strontium ranelate group had a 41% lower risk of a 
new vertebral fracture than the placebo group over the three-year study period (relative risk 
[RR]=0.59; 95% conﬁ  dence interval [CI]: 0.48–0.73; p<0.001). The TROPOS study evaluated 
non-vertebral fracture prevention in 5091 postmenopausal women with a mean age of 77 y. The 
subjects were aged 74 y and over (or 70–74 y with one additional risk factor) and a low femoral 
neck BMD (equivalent to an NHANES III [Third National Health and Nutrition Examination 
Survey] T-score below –2.2). Over the three-year study period there was a 16% reduction in 
all non-vertebral fractures (RR=0.84; 95% CI 0.702–0.995; p=0.04) and a 19% reduction at the 
principal sites for non-vertebral fractures. The TROPOS study was not powered to investigate 
hip fracture risk. However, in a high risk group of women aged 74 y and over and with an 
NHANES III femoral neck T-score less than –2.4 there was a 36% reduction in hip fracture 
risk (RR=0.64; 95% CI: 0.412–0.997; p=0.046). The overall incidence of adverse events did 
not differ signiﬁ  cantly from placebo and were generally mild and transient, the most common 
being nausea and diarrhea. Strontium ranelate is a useful addition to the range of anti-fracture 
treatments available for treating postmenopausal women with osteoporosis and is the only 
treatment proven to be effective at preventing both vertebral and hip fractures in women aged 
80 y and over. 
Keywords: Strontium ranelate, osteoporosis treatment, postmenopausal women, vertebral 
fracture prevention, hip fracture prevention 
Introduction
Strontium ranelate (Les Laboratoires Servier, Neuilly-sur-Seine, France) is a new 
orally administered agent recently licensed in Europe and Australia for the treatment 
of postmenopausal osteoporosis to reduce the risk of vertebral and hip fractures. As an 
alkaline earth element, strontium has close similarities with calcium in its absorption 
in the gut, incorporation into bone, and relatively high renal tubular reabsorption in 
the kidneys (Marshall et al 1973). Since strontium is naturally present in trace amounts 
in the human body (Sowden and Stitch 1957), treatment with strontium ranelate is 
simply making more stable strontium available for incorporation into bone. After 
3 years treatment with strontium ranelate, the molar fraction of strontium in bone is 
about 1%, ie, there is ~1 strontium atom for every 100 calcium atoms in bone tissue 
(Blake and Fogelman 2005). 
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Strontium ranelate is a useful addition to the range of 
anti-fracture treatments available for treating postmenopausal 
women with osteoporosis (Table 1). Its mechanism of 
action appears to be different from other treatments. 
Bisphosphonates (BPs) (Liberman et al 1995; Black et al 
1996; Harris et al 1999; Chesnut et al 2004) and selective 
estrogen receptor modulators (SERMs) (Ettinger et al 
1999) are antiresorptive agents that are believed to work by 
suppressing bone remodeling (Eastell et al 2003). In contrast, 
human recombinant parathyroid hormone (PTH) is an 
anabolic agent that that works by promoting bone formation 
(Lindsay et al 1997; Neer et al 2001). Animal models and 
in vitro studies suggest that strontium ranelate acts in both 
these ways, having both a mild anabolic effect and a mild 
antiresorptive effect on bone tissue (Marie et al 1993; 
Canalis et al 1996). Studies in intact rats given strontium 
ranelate showed increases in bone resistance, in cortical and 
trabecular bone volume, and in bone micro-architecture, 
indicating an improvement in bone quality (Ammann et al 
2004). Treatment with strontium ranelate may therefore 
serve to uncouple bone resorption and bone formation 
and rebalance bone turnover in favor of bone formation 
(SPC 2004). 
The chemical structure of strontium ranelate is composed 
of two atoms of stable strontium combined with organic 
ranelic acid (Figure 1). Strontium is the bone active 
component and makes up 34% by weight of the whole 
molecule, so each 2 g dose of strontium ranelate delivers 
680 mg of elemental strontium. The daily dose comes as 
granules in a sachet that are suspended in water and drunk 
usually at bedtime. The summary of product characteristics 
(SPC) gives a figure of 25% for the gut absorption of 
strontium. This is consistent with the ﬁ  ndings of a recent 
meta-analysis of strontium gut absorption, which reported 
a log normal distribution with a geometric mean of 22.3% 
and 95% conﬁ  dence interval (CI) 10.9% to 45.6%, or about 
a factor of 2 around the geometric mean (Apostoaei 2002). 
If strontium ranelate is prescribed with calcium supplements 
then these latter should be taken at a different time of 
day (ie, at lunch time) to avoid reducing gut absorption. 
Similarly, absorption is affected by food, milk, and milk 
derivatives, and strontium ranelate should be taken at least 
2 h after these products. The suspension of strontium ranelate 
in water is tasteless and the ranelic acid passes through the 
gut largely unabsorbed (SPC 2004).
The two most important requirements of any treatment 
for osteoporosis are firstly that it is proven to be safe 
and secondly that it is effective in reducing fracture risk. 
Evidence of the safety and efﬁ  cacy of strontium ranelate 
comes from two large multinational clinical trials, the 
SOTI (Spinal Osteoporosis Therapeutic Intervention) 
(Meunier et al 2004) and TROPOS (Treatment of Peripheral 
Osteoporosis) (Reginster et al 2005) studies, which were 
Table 1 Treatments for postmenopausal women with 
osteoporosis
Strontium ranelate
Bisphosphonates
 Alendronate
 Ibandronate
 Risedronate
Selective estrogen receptor modulators (SERMS)
 Raloxifene
Parathyroid hormone (PTH)
  Human recombinant PTH (1-34)
Calcium and vitamin D
S
Sr++
Sr++
N
-00C—CH2
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Figure 1 Chemical structure of strontium ranelate (Marie et al 1993). Clinical Interventions in Aging 2006:1(4) 369
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designed to study vertebral and non-vertebral fractures 
respectively. Further clinical data is available from two 
earlier Phase 2 trials, the STRATOS (Strontium Ranelate 
for Treatment of Osteoporosis) (Meunier et al 2002) and 
PREVOS (Prevention of Osteoporosis) (Reginster et al 
2002) studies. These latter were dose ranging studies that 
examined the effects of strontium ranelate treatment on bone 
mineral density (BMD) and biochemical markers of bone 
turnover in patients with established vertebral fractures and 
early postmenopausal women respectively. The STRATOS 
study also provided some fracture data. 
Vertebral fracture prevention by 
strontium ranelate
The evaluation of the efﬁ  cacy of strontium ranelate treatment 
in preventing vertebral fractures was the primary aim of the 
SOTI trial (Meunier et al 2004). A total of 1649 women 
(mean age 69 y) were enrolled and randomized to receive 
either strontium ranelate 2 g/day or placebo. All subjects 
were also given calcium and vitamin D supplements to 
ensure they received the recommended daily intakes. The 
women were aged 50 y and over, at least 5 y postmenopausal, 
had at least 1 previous vertebral fracture and a lumbar spine 
bone mineral density (BMD) less than 0.840 g/cm2 (T-score 
<–2.4 on the Slosman reference range (Slosman et al 1994) 
used for study inclusion criteria, equivalent to a T-score 
<–1.9 on the Hologic manufacturer’s spine reference range). 
Lateral spinal radiographs were performed at baseline and 
then annually, and were evaluated for evidence of new 
vertebral fractures using the Genant semi-quantitative 
method (Genant et al 1993). At the end of the ﬁ  rst year of 
treatment there was a 49% lower risk of a new radiographic 
vertebral fracture in the strontium ranelate group compared 
with the placebo group (incidence 6.4% vs 12.2%; relative 
risk [RR]=0.51; 95% CI: 0.36–0.74; p<0.001). The risk of 
a clinically symptomatic vertebral fracture was 52% lower 
(3.1% vs 6.4%; RR=0.48; 95% CI: 0.29–0.80; p=0.003). 
Over the main three-year study period the strontium 
ranelate group had a 41% lower risk of a new radiographic 
vertebral fracture than the placebo group (incidence 20.9% 
vs 32.8%; RR=0.59; 95% CI: 0.48–0.73; p<0.001), while the 
incidence of clinically symptomatic vertebral fracture was 
38% lower (11.3% vs 17.4%; RR=0.62; 95% CI: 0.47–0.83; 
p<0.001). Over this period the number of patients treated 
to prevent one vertebral fracture (NNT) was 9. The four-
year SOTI study fracture data were recently published in 
a conference abstract (Reginster et al 2006) and show a 
33% reduction in the risk of a new vertebral fracture in the 
strontium ranelate group compared with placebo (RR=0.67; 
95% CI: 0.55–0.81; p<0.001). The 1 y, 3 y, and 4 y data are 
summarized in Figure 2.
The TROPOS study provided further data on the vertebral 
fracture efﬁ  cacy of strontium ranelate (Reginster et al 2005). 
Although not primarily intended to study vertebral fractures, 
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Figure 2 Results for vertebral fracture reduction by strontium ranelate treatment in the SOTI and TROPOS studies (Meunier et al 2004; Reginster et al 2005, 2006). 
Results are shown as the relative risk (RR) and 95% conﬁ  dence intervals. 
Abbreviations: SOTI, Spinal Osteoporosis Therapeutic Intervention; TROPOS, Treatment Of Postmenopausal Osteoporosis.Clinical Interventions in Aging 2006:1(4) 370
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3640 out of 5091 women enrolled in the TROPOS study 
(71%) had annual spinal radiographs. Of these 3640 patients, 
two-thirds (66.4%) had no prevalent vertebral fracture at 
inclusion. Over three years the overall reduction in vertebral 
fracture risk was 39% (RR=0.61; 95% CI: 0.51–0.73; 
p<0.001), and in the first year the reduction was 45% 
(RR=0.55; 95% CI: 0.39–0.77; p<0.001). The anti-fracture 
efﬁ  cacy at 3y was similar for patients with and without 
vertebral fractures at baseline. The pooled 3-year data from 
the SOTI and TROPOS studies gave a total population of 
5082 women for the evaluation of vertebral fracture risk and 
showed an overall reduction in fracture risk of 40% over three 
years (RR=0.60; 95% CI: 0.53–0.69; p<0.001) (Roux et al 
2006). The recently presented 5-year TROPOS data show 
a 24% reduction in vertebral fracture risk (RR=0.76; 95% 
CI: 0.65–0.87; p<0.001) (Reginster et al 2006). Although 
both the SOTI and TROPOS data show a slight decline in 
antifracture efﬁ  cacy the longer treatment is given (Figure 2), 
such a trend is expected since with the Kaplan-Meier analysis 
patients are censored after their ﬁ  rst fracture and with time 
the remaining subjects in the treated and placebo groups 
become less well matched. 
One interesting aspect of the SOTI and TROPOS studies 
compared with previous osteoporosis trials was the relatively 
advanced age of many of the subjects (Seeman et al 2006). 
Taken together, the two studies enrolled 1556 patients over 
80 years at inclusion (23.1% of the entire study population) 
(SPC 2004). The pooled analysis of the studies for vertebral 
fracture risk showed no evidence of a treatment-by-age 
interaction (p=0.652). The RR reduction was 37% (p=0.003) 
in the younger women (<70 years), 42% (p<0.001) in women 
70–80 years of age, and 32% (p=0.013) in the elderly 
(women ≥80 years of age) (Roux et al 2006). 
Some vertebral fracture data was also published for 
the STRATOS study (Meunier et al 2002). However, this 
was a much smaller study with only 90 patients in each of 
four groups (placebo, 0.5, 1 and 2 g/day strontium ranelate) 
and over the full 2-years of the trial the results were not 
statistically signiﬁ  cant (2 g/day group at 2 y: RR=0.77; 95% 
CI: 0.54–1.09). 
Non-vertebral fracture prevention 
by strontium ranelate
The efﬁ  cacy of strontium ranelate treatment in preventing 
non-vertebral fractures was investigated in the TROPOS trial, 
a study of 5091 women with a mean age of 77 y (Reginster 
et al 2005). Women were eligible for this study if they had 
a femoral neck BMD less than 0.600 g/cm2 (T-score <−2.5 
on the Slosman reference range [Slosman et al 1994] used 
for study inclusion criteria, equivalent to a T-score <−2.2 
on the widely adopted NHANES III (Third National Health 
and Nutrition Examination Survey) hip reference range 
[Looker et al 1998]) and were aged 74 y or over, or were 
between 70 y and 74 y and had at least one additional risk 
factor such as a history of previous osteoporotic fracture 
or a maternal history of fracture. As in the SOTI trial, 
the subjects were randomized to receive either strontium 
ranelate 2 g/day or placebo, and also received calcium and 
vitamin D supplements. All non-vertebral fractures were 
recorded with the exception of the coccyx, skull, jaw, 
face, phalanx (ﬁ  ngers and toes) and ankle, since these 
latter were not regarded as being related to osteoporosis. 
Over the main 3 year follow-up period there was a 16% 
reduction in all non-vertebral fractures (incidence 11.2% vs 
12.9%; RR=0.84; 95% CI: 0.702–0.995; p=0.04; number 
needed to treat [NNT]=59) (Figure 3). For the principal 
non-vertebral fracture sites (hip, wrist, pelvis, sacrum, ribs, 
sternum, clavicle, humerus) there was a 19% reduction in 
fracture risk (incidence 8.7% vs 10.4%; RR=0.81; 95% 
CI: 0.66–0.98; p=0.031; NNT=59). Overall the relative 
risk of hip fracture was reduced by 15%, but this ﬁ  gure was 
not statistically signiﬁ  cant and the trial was not powered 
to investigate anti-fracture efﬁ  cacy at this site. However, 
in a subgroup of high risk patients aged 74 y and over and 
with an NHANES III femoral neck T-score <−2.4 there 
was a 36% reduction in hip fracture risk (incidence 4.3% vs 
6.4%; RR=0.64; 95% CI: 0.412–0.997; p=0.046; NNT=48) 
(Figure 3). The 5-year results of the TROPOS study show 
continuing long-term efﬁ  cacy with a 15% reduction in 
non-vertebral fractures (RR = 0.85; 95% CI: 0.73–0.99; 
p=0.03) (Reginster et al 2006) (Figure 3).
The smaller SOTI study (Meunier et al 2004) was not 
powered to investigate non-vertebral fracture risk. Non-
vertebral fractures were recorded in 234 women (112 in the 
strontium ranelate group and 122 in the placebo group) over 
the 3-year study (incidence 15.5% vs 16.8%; RR=0.90; 95% 
CI: 0.69–1.17). In the analysis of the pooled data from the 
SOTI and TROPOS studies the overall reduction in non-
vertebral fracture risk was 15% (incidence 11.6% vs 13.1%; 
RR=0.85; 95% CI: 0.74–0.99; p=0.03) (Roux et al 2006). 
In the cohort of SOTI and TROPOS women aged 80 years 
and over at enrolment the reduction in non-vertebral fracture 
risk was 31% (incidence 14.2% vs 19.7%; RR=0.69; 95% 
CI: 0.52–0.92; p=0.011) (Seeman et al 2006).Clinical Interventions in Aging 2006:1(4) 371
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Figure 3 Results for non-vertebral fracture reduction by strontium ranelate in the TROPOS study (Reginster et al 2005, 2006). Results are shown as the relative risk (RR) 
and 95% conﬁ  dence intervals. 
Abbreviations: TROPOS, Treatment Of Postmenopausal Osteoporosis.
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Patient safety in the strontium 
ranelate trials
During the SOTI and TROPOS trials a total of 3352 patients 
were exposed to strontium ranelate, 2315 of them for at 
least 36 months (Meunier et al 2004; Reginster et al 2005). 
The overall incidence of adverse events did not differ 
signiﬁ  cantly from placebo and were generally mild and 
transient. The most common were nausea (6.6% of patients 
taking strontium ranelate vs 4.3% in those taking placebo) 
and diarrhea (6.5% vs 4.6%). However, if constipation is 
reduced the latter effect may be beneﬁ  cial. The adverse 
reactions in the two studies thought possibly attributable 
to strontium ranelate are listed in Table 2. After 3 months 
there were no differences between strontium ranelate and 
placebo groups with respect to nausea and diarrhea. In both 
studies a small decrease in serum calcium concentration 
and a small increase in serum phosphate was noted in the 
strontium ranelate group, but these and other small changes 
in biochemistry were without clinical consequence (SPC 
2004). 
In the two Phase 3 studies strontium ranelate treatment 
was found to be associated with an increase in the annual 
incidence of venous thromboembolism (VTE) including 
pulmonary embolism (SPC 2004). This effect was observed 
over 4 years and was approximately 0.7% with a RR of 1.42 
(95% CI: 1.02–1.98; p=0.036). The cause of this ﬁ  nding is 
unknown. The SPC advises that strontium ranelate should 
be used with caution in patients at increased risk of VTE, 
including patients with a previous history of VTE. 
The SPC also states that strontium ranelate is not 
recommended in patients with severe renal impairment 
(glomerular filtration rate below 30 mL/min). Plasma 
strontium levels will be higher in such patients and the 
implications for bone safety are not known. 
The effect of strontium ranelate 
treatment on bone mineral 
density
All the clinical trials of strontium ranelate (Meunier et al 
2002, 2004; Reginster et al 2002, 2005) show impressive 
increases in BMD compared with BPs (Liberman et al 
Table 2 Adverse events pooled for the SOTI (Meunier et al 
2004) and TROPOS (Reginster et al 2005) studies
Adverse event    Strontium ranelate   Placebo 
 (N=3352)   (N=3317) 
Nausea   222  (6.6%)   142  (4.3%) 
Diarrhea   219  (6.5%)   154  (4.6%) 
Loose stools   36  (1.1%)   6  (0.2%) 
Headache   101  (3.0%)   79  (2.4%) 
Dermatitis   69  (2.1%)   54  (1.6%) 
Eczema   50  (1.5%)   40  (1.2%) 
Allergic dermatitis   33  (1.0%)   18  (0.5%) 
Abbreviations: SOTI, Spinal Osteoporosis Therapeutic Intervention; TROPOS, 
Treatment Of Postmenopausal Osteoporosis.Clinical Interventions in Aging 2006:1(4) 372
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1995; Black et al 1996; Harris et al 1999; Chesnut et al 
2004) and SERMs (Ettinger et al 1999), and comparable 
with PTH (Lindsay et al 1997; Neer et al 2001) (Figure 4). 
After 3 years treatment the SOTI data showed BMD 
increases compared with placebo of 14.4% at the spine, 
9.8% at the total hip site, and 8.3% at the femoral neck 
(Meunier et al 2004). These large changes may provide a 
useful way of monitoring patient compliance (Fogelman 
and Blake 2005). However, caution is necessary in 
interpreting the BMD increases as a real change in bone 
mass because much of the effect is due to the higher 
atomic number of strontium (Z=38) compared with 
calcium (Z=20) (Blake and Fogelman 2005). When BMD 
is measured by dual energy X-ray absorptiometry (DXA), 
strontium atoms in bone attenuate X-rays more strongly 
than calcium causing BMD to be overestimated. This 
effect was studied quantitatively by Pors Nielsen et al 
(1999) who constructed phantoms containing mixtures 
of calcium and strontium hydroxyapatite that were 
scanned on different manufacturers’ DXA systems. They 
concluded that the same factor (a 1% molar ratio of Sr/
(Ca+Sr) causing a 10% overestimation of BMD) applied 
to all the DXA brands studied. Since 3 years treatment 
with strontium ranelate results in a molar ratio of ~1%, it 
is clear that a significant percentage of the BMD increase 
in the clinical trial data can be explained by the increased 
attenuation due to the bone strontium content (Blake and 
Fogelman 2006).
The most detailed discussion of the size of the BMD 
artefact produced by strontium ranelate treatment is that 
included in the report of the STRATOS trial (Meunier 
et al 2002). In this study 17 patients had iliac crest bone 
biopsies to measure bone strontium content (BSC) at 
1 year and 64 patients at 2 years. At each time point 
a linear relationship was found between the iliac crest 
BSC and the area under the curve of strontium plasma 
concentration against time (AUC), and this was used to 
predict BSC values in patients who did not have a bone 
biopsy. For the 2 g/day strontium ranelate group it can 
be inferred from the raw and corrected STRATOS study 
BMD data that the mean iliac crest BSC was 0.8% at 
12 months and 1.3% at 2 years. These BSC values were 
corrected by a factor of 0.61 for the ratio of spine to iliac 
crest BSC measured in female monkeys (Dahl et al 2001), 
and then combined with the phantom data of Pors Nielsen 
et al (1999) to adjust the raw spine BMD measurements. 
The strontium ranelate SPC document cites a factor of 
50% for the correction of the measured BMD changes at 
the end of 3 years of treatment to allow for this effect. 
This should be taken into account when interpreting 
BMD changes during treatment with strontium ranelate. 
Radionuclide studies of the long-term retention of strontium 
Figure 4 (A) Data from the SOTI study (Meunier et al 2004) showing the effect of 3 years treatment with strontium ranelate (2 g/day) on spine bone mineral density 
(BMD). The BMD values have not been adjusted for the bone strontium content. (B) Mean percentage changes in spine BMD from baseline to 3 years in patients receiving 
active treatment in four clinical trials: (i) raloxifene (60 mg/day) (Ettinger et al 1999); (ii) risedronate (5 mg/day) (Harris et al 1999); (iii) alendronate (10mg/day) (Liberman 
et al 1995); (iv) hPTH(1-34) and oestrogen (Lindsay et al 1997). 
Abbreviations: hPTH, Human recombinant parathyroid hormone; SOTI, Spinal Osteoporosis Therapeutic Intervention.
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in bone using whole body counters (Marshall et al 1973) 
suggest that much of this BMD artefact will persist for at 
least 10 years after patients discontinue treatment (Blake 
and Fogelman 2006).
The effect of strontium ranelate 
treatment on biochemical markers 
of bone turnover
Follow-up measurements of changes in bone resorption 
and bone formation have played an important part in 
characterizing the clinical response in trials of other 
treatments for postmenopausal osteoporosis (Black et al 
1996; Lindsay et al 1997; Harris et al 1999; Ettinger et al 
1999; Eastell et al 2003; Chesnut et al 2004). For example, 
with the more potent BPs there is an almost immediate 
(within 1 month) reduction of 30%–50% in biochemical 
markers of bone resorption followed by a similar but delayed 
(3 to 6 month) reduction in markers of bone formation 
(Garnero et al 1994). For the potent anabolic agent human 
recombinant PTH there is an increase of about 50% in 
markers of both bone formation and bone resorption within 
6 months of patients starting treatment. Based on pre-clinical 
studies, strontium ranelate is believed to exert an uncoupling 
effect on bone turnover by enhancing bone formation at 
the same time that it suppresses bone resorption (Marie 
et al 1993). It was therefore of interest to see whether the 
strontium ranelate trials provided confirmation of this 
behaviour. 
Biochemical marker measurements were reported for 
the SOTI study (Meunier et al 2004) but not TROPOS 
(Reginster et al 2005). Unfortunately, the SOTI biochemical 
marker data were affected by some unexplained variations 
affecting the measurements for both the strontium ranelate 
and placebo groups. Nevertheless, the SOTI study authors 
inferred that after 3 months of treatment the serum 
concentration of bone speciﬁ  c alkaline phosphatase (BSAP), 
a bone formation marker, increased by 8.1% in the strontium 
ranelate group compared with placebo (p<0.001) while the 
concentration of serum C-telopeptide cross-links (CTX), 
a bone resorption marker, was lower by 12.2% (p<0.001), 
and these changes were sustained throughout the 3-year 
study. The biochemical marker data from the SOTI study 
therefore appeared to conﬁ  rm the expected effect of a mild 
(compared with a potent anabolic agent) promotion of bone 
formation, and a mild (compared with potent antiresorptive 
agents) suppression of bone resorption, and are in line with 
the results of pre-clinical animal and in vitro studies (Marie 
et al 1993; Canalis et al 1996; Ammann et al 2004). 
Biochemical marker data were also reported for the 
STRATOS (Meunier et al 2002) and PREVOS (Reginster 
et al 2002) trials. However, both these studies were smaller 
than the SOTI trial with patients randomized to a range of 
treatment doses. In the STRATOS study BSAP increased by 
11% at 24 months in the 2 g/day group (p<0.05), while urinary 
excretion of type 1 collagen cross-linked N-telopeptide 
pyridinoline (NTX) was reduced by 10.1% compared with 
placebo at the same time point. In the PREVOS study 
similar trends were seen, but most of the differences were 
not statistically signiﬁ  cant. 
The effect of strontium 
ranelate treatment on bone 
histomorphometry
A considerable effort was made in the strontium ranelate 
trials to obtain transiliac bone biopsies to evaluate bone 
safety and assess the mechanism of action at the bone tissue 
level (Meunier et al 2002, 2004; Reginster et al 2005). Bone 
histomorphometry data from the STRATOS, SOTI, and 
TROPOS patients at baseline, 1 y, 2 y, 3 y, 4 y and 5 y from 
the start of treatment were reviewed by Arlot et al (2005). 
Data were available for 49 patients treated with strontium 
ranelate for between 1 y and 5 y, and for 87 patients either 
at study baseline or in those randomized to the placebo 
group. The positive effect of strontium ranelate on bone 
formation was conﬁ  rmed by a higher osteoblastic surface 
area (Ob.S/BS) in treated compared with untreated patients 
(+38%; p=0.047) and a greater mineral apposition rate 
(MAR) in trabecular (+8%; p=0.008) and cortical (+11%; 
p=0.033) bone. There was no signiﬁ  cant change in activation 
frequency. The effect on bone resorption consisted of 
trends towards lower endosteal eroded surfaces, endosteal 
and trabecular osteoclast surfaces, and osteoclast numbers, 
none of which were statistically signiﬁ  cant. In terms of 
bone safety, osteoid thickness was found to be signiﬁ  cantly 
lower and MAR signiﬁ  cantly higher in treated patients with 
no change in osteoid volume or mineralization lag time 
demonstrating that primary mineralization was not impaired. 
Overall, the results are consistent with the mild stimulation 
of bone formation.
Conclusions
The results of the SOTI and TROPOS studies conﬁ  rm that 
strontium ranelate is a safe and effective treatment to prevent Clinical Interventions in Aging 2006:1(4) 374
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vertebral fractures and hip fractures in women with 
postmenopausal osteoporosis. The 40% reduction in 
vertebral fracture risk found in the pooled analysis (Roux 
et al 2006) is similar to that found in trials of other 
osteoporosis treatments including alendronate (Black et al 
1996), risedronate (Harris et al 1999), ibandronate (Chesnut 
et al 2004), and raloxifene (Ettinger et al 1999). Strontium 
ranelate has also been proven to reduce non-vertebral 
fracture risk by 15% (Roux et al 2006). This includes 
the prevention of hip fractures in older patients with a 
femoral neck BMD T-score consistent with the diagnosis 
of osteoporosis. Interestingly, because of the generally 
elderly population enrolled in the SOTI and TROPOS 
studies, strontium ranelate is the only treatment proven to 
be effective at preventing both vertebral and non-vertebral 
fractures in patients aged 80 years and over (Seeman et al 
2006). Data from bone biopsies and biochemical markers of 
bone turnover seem to conﬁ  rm the hypothesis that strontium 
ranelate may have a dual mode of action that has the effect 
of rebalancing bone turnover in favor of bone formation. 
No studies have yet examined the beneﬁ  t of combining 
strontium ranelate with another treatment, for example a 
BP. Theoretically the administration of strontium ranelate 
in combination with a potent BP could have an adverse 
effect on both the uptake and the pharmacological action of 
strontium in bone because of the reduction in osteoblastic 
activity by the BP. In many patients strontium ranelate 
treatment has an impressive effect on BMD, and the large 
BMD increase may prove a useful way of monitoring patient 
response (Fogelman and Blake 2005). However, clinicians 
should be aware that at least 50% of the observed BMD 
increase is an artefact caused by the high bone strontium 
content (SPC 2004). This artefact will persist for many years 
after the patient discontinues therapy and will need to be 
taken into account in the interpretation of future BMD scans 
in patients who have previously been treated with strontium 
ranelate (Blake and Fogelman 2006).
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